Drug
Acamprosate (Campral)
Acamprosate (Campral) is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_4
2
50%
Ph phase_3
1
25%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)
Trials by Status
completed375%
withdrawn125%
Recent Activity
0 active trials
Showing 4 of 4
withdrawnphase_4
Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)
NCT00655967
completedphase_4
Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic
NCT00381043
completedphase_2
Acamprosate Treatment: Mechanisms of Action
NCT00004552
completedphase_3
COMBINE (Acamprosate/Naltrexone)
NCT00006206
Clinical Trials (4)
Showing 4 of 4 trials
NCT00655967Phase 4
Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE)
NCT00381043Phase 4
Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic
NCT00004552Phase 2
Acamprosate Treatment: Mechanisms of Action
NCT00006206Phase 3
COMBINE (Acamprosate/Naltrexone)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4